‘Our track record in R&D was not great for a few years...’
Merck KGaA broke free from a decade of failures this year with a new drug in the hottest area of oncology. The next 12 months will begin to show whether it was more than just a lucky break.
Success could reshape the view of a drugmaker eclipsed by rivals including its larger U.S. offspring Merck. after its labs yielded only one major new medicine in more than 12 years.
